Physician profile
Luis Vasquez
NPI 1760407084
$1,477.03
in general payments reported to CMS, 2019-2025
13 companies · $502 in 2025
The $502 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $163 · 2023: $155 · 2024: $275 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $140.30 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $97.09 | 2025 | Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.39 | 2025 | Caplyta |
| Novo Nordisk INC | $80.81 | 2022-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $66.98 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $64.25 | 2021 | |
| Lilly USA, LLC | $47.08 | 2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $46.87 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $31.50 | 2025 | |
| Phathom Pharmaceuticals, INC. | $28.67 | 2025 | Voquezna |
| Shield Therapeutics INC | $22.07 | 2025 | |
| Dexcom, INC. | $18.40 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.